ArticleMetabolites2021
Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk.
Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Lipid profiles in patients with juvenile idiopathic arthritis: a systematic literature review and meta-analysis.Lipids in health and disease · 2023Pooled it
- Atherosclerosis Progression in the APPLE Trial Can Be Predicted in Young People With Juvenile-Onset Systemic Lupus Erythematosus Using a Novel Lipid Metabolomic Signature.Arthritis & rheumatology (Hoboken, N.J.) · 2024Trial
- Association of metabolic and inflammation vulnerabilities with systemic lupus erythematosus: a prospective UK Biobank study.Frontiers in immunology · 2026Article
- The plasma metabolome of juvenile idiopathic arthritis varies according to subtype and underlying inflammatory status.Pediatric rheumatology online journal · 2024Article
- Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk.Rheumatology (Oxford, England) · 2024Article
- Analysis of hyperlipidemia risk factors among pilots based on physical examination data: A study using a multilevel propensity score models.Experimental and therapeutic medicine · 2024Article
- Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.Clinical and experimental immunology · 2024Article
- Systemic lupus in the era of machine learning medicine.Lupus science & medicine · 2024Review
- Cardiovascular risk and inflammation in a population with autoimmune diseases: a narrative review.Frontiers in immunology · 2024Review
- Role of Altered Metabolism of Triglyceride-Rich Lipoprotein Particles in the Development of Vascular Dysfunction in Systemic Lupus Erythematosus.Biomolecules · 2023Article
- Impact of puberty, sex determinants and chronic inflammation on cardiovascular risk in young people.Frontiers in cardiovascular medicine · 2023Review
- Serum Metabolomics Analysis of Skin-Involved Systemic Lupus Erythematosus: Association of Anti-SSA Antibodies with Photosensitivity.Journal of inflammation research · 2023Article
- Comorbidity in young patients with juvenile systemic lupus erythematosus: how can we improve management?Clinical rheumatology · 2022Article
- Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cardiovascular disease (CVD) is a leading cause of mortality in patients with juvenile-onset systemic lupus erythematosus (JSLE) associated with atherosclerosis. The interplay between dyslipidaemia and inflammation-mechanisms that drive atherosclerosis-were investigated retrospectively in adolescent JSLE patients using lipoprotein-based serum metabolomics in patients with active and inactive disease, compared to healthy controls (HCs). Data was analysed using machine learning, logistic regression, and linear regression. Dyslipidaemia in JSLE patients was characterised by lower levels of small atheroprotective high-density lipoprotein subsets compared to HCs. These changes were exacerbated by active disease and additionally associated with significantly higher atherogenic very-low-density lipoproteins (VLDL) compared to patients with low disease activity. Atherogenic lipoprotein subset expression correlated positively with clinical and serological markers of JSLE disease activity/inflammation and was associated with disturbed liver function, and elevated expression of T-cell and B-cell lipid rafts (cell signalling platforms mediating immune cell activation). Finally, exposing VLDL/LDL from patients with active disease to HC lymphocytes induced a significant increase in lymphocyte lipid raft activation compared to VLDL/LDL from inactive patients. Thus, metabolomic analysis identified complex patterns of atherogenic dyslipidaemia in JSLE patients associated with inflammation. This could inform lipid-targeted therapies in JSLE to improve cardiovascular outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.